```markdown
field_name_1: value_1
field_name_2: value_2
field_name_3: value_3
field_name_4: None

# Page 1 of 5
Start of treatment, start date: 05/23/2024
Continuation of therapy, date of last treatment: None
Precertification Requested By: Erran Rostami
Phone: 615-343-1176
Fax: 615-343-1219

A. PATIENT INFORMATION
First Name: Shakh
Last Name: Abdulla
DOB: 04/01/2001
Address: 8327 Broadway Ln, APT D
City: Knoxville
State: TN
ZIP: 37923
Home Phone: 865-395-3958
Work Phone: None
Cell Phone: 865-395-0481
E-mail: None
Current Weight: None
Height: None
Allergies: No Known Allergies

B. INSURANCE INFORMATION
Member ID #: LAJM14345116
Does patient have other coverage? No
Group #: 435000
Carrier Name: BC TENNCARE
Insured: Abdulla, Shakh

C. PRESCRIBER INFORMATION
First Name: Hao
Last Name: Gu
Check one: M.D.
Address: 3320 Montgomery Dr
City: Nashville
State: TN
ZIP: 37361
Phone: 614-936-0065
Fax: None
St Lic #: None
NPI #: 1154611523
DEA #: None
UPIN: None
Provider Email: None
Office Contact Name: None
Phone: None

D. DISPENSING PROVIDER ADMINISTRATION INFORMATION
Place of Administration: Outpatient Infusion Center
Dispensing Provider Pharmacy: None
Name: Golden Gate Infusion Center
Phone: 614-295-7655
Fax: 614-225-3355
TIN: None
PIN: None
NPI: None

E. PRODUCT INFORMATION
Request is for: Truxima (rituximab-abbs)
Dose: 694 mg 
Directions for Use: Day 1, 15 Load Then Once Every 24 Weeks
HCPCS Code: None

F. DIAGNOSIS INFORMATION
Primary ICD Code: G35
Other ICD Code: None

G. CLINICAL INFORMATION
Yes ☐ No ☐ Has the patient had prior therapy with the requested product within the last 365 days? Yes
No ☐ Has the patient had a trial and failure of any of the following rituximab biosimilars? No
No ☐ Has the patient had an adverse reaction to any of the following rituximab biosimilars? No
Please explain if there are any contraindications or other medical reason(s) that the patient cannot use any of the following preferred biosimilar products when indicated for the patient's diagnosis? Truxima (rituximab-abbs); Approved for use

# Page 2 of 5
Yes ☐ No ☐ Will Rituxan (rituximab) be used concomitantly with apremilast, tofacitinib, or other biologic DMARDs (e.g., adalimumab, infliximab)? No 
Acute lymphoid leukemia: 
Yes ☐ No ☐ Does the patient have a documented diagnosis of Philadelphia chromosome-negative acute lymphoid leukemia (ALL)? No
Yes ☐ No ☐ Is Rituxan (rituximab) being used as induction consolidation therapy? No

Autoimmune hemolytic anemia:
Yes ☐ No ☐ Does the patient have a documented diagnosis of refractory autoimmune hemolytic anemia? No

Anti-neutrophil cytoplasmic antibody-associated (ANCA-associated) vasculitides: None

Autoimmune blistering diseases, corticosteroid-refractory: None

B-cell lymphomas
No selection applies to the patient.

Cryoglobulinemia:
Yes ☐ No ☐ Does the patient have a documented diagnosis of cryoglobulinemia? No
Yes ☐ No ☐ Is there clinical documentation that the treatment with corticosteroids and other immunosuppressive agents was ineffective? No

# Page 3 of 5
Patient First Name: Shakh
Patient Last Name: Abdulla
Patient Phone: 865-395-0481
Patient DOB: 04/01/2001

Castleman's disease:
Yes ☐ No ☐ Does the patient have a documented diagnosis of multicentric Castleman's disease (angiofollicular lymph node hyperplasia)? No

Central nervous system lymphomas: [ ] none of the above

Chronic or small lymphocytic leukemia: [ ] none of the above

Graft versus host disease, chronic:
Yes ☐ No ☐ Is there a documentation that Rituxan (rituximab) being used as last-resort treatment for chronic graft versus host disease (GVHD)? No

Hairy cell leukemia: [ ] none of the above

Heart and solid organ transplant:
Yes ☐ No ☐ Is there a documentation that Rituxan (rituximab) is being used for treatment or prevention (desensitization) of highly sensitized patients with antibody mediated rejection in heart transplant recipients and other solid organ transplant recipients? No

# Page 4 of 5
Rheumatoid Arthritis: No

Sjögren syndrome:
Yes ☐ No ☐ Does the patient have a documented diagnosis of Sjögren's syndrome? No
Yes ☐ No ☐ Was treatment with corticosteroids and other immunosuppressive agents ineffective? No

Thrombotic thrombocytopenic purpura:
Yes ☐ No ☐ Does the patient have a documented diagnosis of refractory thrombotic thrombocytopenic purpura (TTP)? No

Waldenstrom's macroglobulinemia:
Yes ☐ No ☐ Does the patient have a documented diagnosis of Waldenström macroglobulinemia? No

For Continuation Requests:
Yes ☐ No ☐ Is this continuation request a result of the patient receiving samples of Rituxan (rituximab)? No
Please indicate the length of time on Rituxan (rituximab): None
```